This is a working overview of prohibited substance, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
However, the Whig-Radical amalgam could not become a true modern political party while it was dominated by aristocrats and it was not until the departure of the "Two Terrible Old Men", Russell and Palmerston, that Gladstone could become the first leader of the modern Liberal Party. This was brought about by Palmerston's death in 1865 and Russell's retirement in 1868. After a brief Conservative government (during which the Second Reform Act was passed by agreement between the parties), Gladstone won a huge victory at the 1868 election and formed the first Liberal government. The establishment of the party as a national membership organisation came with the foundation of the National Liberal Federation in 1877. The philosopher John Stuart Mill was also a Liberal MP from 1865 to 1868.
Eyes: Chronic conjunctivitis, scars on cornea, corneal opacities, early cataracts Respiratory tracts: Obstructive and/or restrictive disease, pulmonary fibrosis, aggravation of tuberculosis and chronic bronchitis Neurological system: Impairment of memory, finer motor skills, numbness, etc. Psychological problems: Post traumatic stress disorder (PTSD) Children's health: Peri- and neonatal death rates increased. Failure to grow, intellectual impairment, etc. Missing or insufficient fields for research are female reproduction, chromosomal aberrations, cancer, immune deficiency, neurological sequelae, post traumatic stress disorder (PTSD) and children born after the disaster. Late cases that might never be highlighted are respiratory insufficiency, cardiac insufficiency (cor pulmonale), cancer and tuberculosis. Bhopal now has high rates of birth defects and records a miscarriage rate 7x higher than the national average. A 2014 report in Mother Jones quotes a "spokesperson for the Bhopal Medical Appeal, which runs free health clinics for survivors" as saying "An estimated 120,000 to 150,000 survivors still struggle with serious medical conditions including nerve damage, growth problems, gynaecological disorders, respiratory issues, birth defects, and elevated rates of cancer and tuberculosis."
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. They do this by cleaving the peptide bonds within proteins by hydrolysis, a reaction where water breaks bonds. Proteases are involved in numerous biological pathways, including digestion of ingested proteins, protein catabolism (breakdown of old proteins), and cell signaling. In the absence of functional accelerants, proteolysis would be very slow, taking hundreds of years. Proteases can be found in all forms of life including viruses. They have independently evolved multiple times, and different classes of protease can perform the same reaction by completely different catalytic mechanisms.
Sources: en.wikipedia.org
Insight into the biosynthesis of the isopropoxy-2-naphthonate appendage was similarly gained by comparative analysis of the ked cluster to those of neocarzinostatin and maduropeptin, enediynes with naphthonate or benzoate substructures, respectively. Five genes, KedN1–N5, bear high sequence homology with the enzymes responsible for naphthonate synthesis in neocarzinostatin—consequently, the intermediacy of 3,6,8-trihydroxy-2-naphthoic acid is proposed in kedarcidin biosynthesis. This compound is believed to be oxygenated to the 3,6,7,8-tetrahydroxy derivative, then triply O-methylated by KedN1, an O-methyltransferase. To furnish the unique isopropoxy substituent, Shen et al. invoke double C-methylation of the corresponding methoxy group by the radical SAM methyltransferase KedN5.
PUS 1 is located in the nucleus and modifies tRNA at different locations, U44 of U2 snRNA, and U28 of U6 snRNA. Studies found that PUS 1 expression increased during environmental stress and is important for regulating the splicing of RNA. Also, that PUS 1 is necessary for taking the tRNA made in the nucleus and sending them to the cytoplasm. PUS 2 is very similar to PUS 1, but located in mitochondria and only modifies U27 and U28 of mito-tRNA. This protein modifies the mitochondrial tRNA, which has a lesser amount of pseudouridine modifications compared to other tRNAs. Unlike most mitochondria located proteins, PUS 2 has not been found to have a mitochondrial targeting signal or MTS. PUS 3 is a homolog to PUS 1, but modifies different places of the tRNA (U38/39) in the cytoplasm and mitochondria. This protein is the most conserved of the TruA family. A decrease in modifications made by PUS 3 was found when the tRNA structure is improperly folded. Along with tRNA, the protein targets ncRNA and mRNA; further research is still needed as to the importance of this modification. PUS 3, along with PUS 1, modify the steroid activator receptor in humans.
Bush pursued many educational initiatives, such as increasing the funding for the National Science Foundation and National Institutes of Health in his first years of office and creating education programs to strengthen the grounding in science and mathematics for American high school students. Funding for the NIH was cut in 2006, the first such cut in 36 years, due to rising inflation. One of the administration's early major initiatives was the No Child Left Behind Act, which aimed to measure and close the gap between rich and poor student performance, provide options to parents with students in low-performing schools, and target more federal funding to low-income schools. This landmark education initiative passed with broad bipartisan support, including the support of Senator Ted Kennedy of Massachusetts. It was signed into law by Bush in early 2002. Many contend that the initiative has been successful, as cited by the fact that students in the U.S. have performed significantly better on state reading and math tests since Bush signed "No Child Left Behind" into law. Critics argue that it is underfunded and that NCLBA's focus on "high-stakes testing" and quantitative outcomes is counterproductive. On November 1, 2005, Bush launched a National Strategy for Pandemic Influenza, which culminated in an implementation plan published by the Homeland Security Council in May 2006.
Sources: en.wikipedia.org
In 2002 David Evans et al. observed a very stable neutral tetrahedral intermediate in the reaction of N-acylpyrroles with organometallic compounds, followed by protonation with ammonium chloride producing a carbinol. The C1-N1 bond [147.84(14) pm] is longer than the usual Csp3-Npyrrole bond which range from 141.2-145.8 pm. In contrast, the C1-O1 bond [141.15(13) pm] is shorter than the average Csp3-OH bond which is about 143.2 pm. The elongated C1-N1, and shortened C1-O1 bonds are explained with an anomeric effect resulting from the interaction of the oxygen lone pairs with the σ*C-N orbital. Similarly, an interaction of an oxygen lone pair with σ*C-C orbital should be responsible for the lengthened C1-C2 bond [152.75(15) pm] compared to the average Csp2-Csp2 bonds which are 151.3 pm. Also, the C1-C11 bond [152.16(17) pm] is slightly shorter than the average Csp3-Csp3 bond which is around 153.0 pm.
{\displaystyle {\begin{aligned}\rho \left({\partial _{t}u_{r}}+u_{r}{\partial _{r}u_{r}}+u_{z}{\partial _{z}u_{r}}\right)&=-{\partial _{r}p}+\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{r}}\right)+{\partial _{z}^{2}u_{r}}-{\frac {u_{r}}{r^{2}}}\right)+\rho g_{r}\\\rho \left({\partial _{t}u_{z}}+u_{r}{\partial _{r}u_{z}}+u_{z}{\partial _{z}u_{z}}\right)&=-{\partial _{z}p}+\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{z}}\right)+{\partial _{z}^{2}u_{z}}\right)+\rho g_{z}\\{\frac {1}{r}}\partial _{r}\left(ru_{r}\right)+{\partial _{z}u_{z}}&=0.\end{aligned}}}
Bog bodies are human remains which have been discovered in peat bogs around the world. They have been preserved naturally to varying degrees due to the specific conditions of peat bogs. Despite their natural preservation, these remains are sensitive to deterioration after being removed from their original locations. Freeze-drying is an accepted method of preserving bog bodies in museum collections. Some bog body discoveries include the Tollund Man of Denmark, the Elling Woman of Denmark, the Cashel Man of Ireland, the Huldremose Woman of Denmark, the Girl of the Uchter Moor of Germany, the Lindow Man of England, and the Yde Girl of the Netherlands. For a more comprehensive list of examples, see List of bog bodies. A record of the preservation of the Tollund Man's head, which took place in 1951 and involved replacing the bog water in the cells with liquid paraffin wax, can be read on the Tollund Man's website hosted by the Silkeborg Public Library, Silkeborg Museum, and Amtscentret for Undervisning.
== Causes == The NIH states: "The causes of most cases of reactive hypoglycemia are still open to debate. Some researchers suggest that certain people may be more sensitive to the body's normal release of the hormone epinephrine, which causes many of the symptoms of hypoglycemia. Others believe deficiencies in glucagon secretion might lead to reactive hypoglycemia. Several other hormones are responsible for modulating the body's response to insulin, including cortisol, growth hormone and sex hormones. Untreated or under-treated hormonal disorders such as adrenal insufficiency (see also Addison's disease) or growth hormone deficiency can therefore sometimes cause insulin hypersensitivity, and reactive hypoglycemia. Stomach bypass surgery or hereditary fructose intolerance are believed to be causes, albeit uncommon, of reactive hypoglycemia. Myo-inositol or 1D-chiro-inositol withdrawal can cause temporary reactive hypoglycemia. There are several kinds of reactive hypoglycemia:
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.